<DOC>
	<DOCNO>NCT03100734</DOCNO>
	<brief_summary>The primary objective evaluate effectiveness Benepali participant Rheumatoid Arthritis ( RA ) axial spondyloarthritis ( axSpA ) , include participant Ankylosing Spondylitis ( AS ) non-radiographic axSpA , follow transition treatment Enbrel . The secondary objective study evaluate safety follow transition Enbrel Benepali evaluate patient-reported outcome follow transition Enbrel Benepali .</brief_summary>
	<brief_title>Observational Study Evaluate Real-Life Effectiveness Benepali Following Transition From Enbrel</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Key Must diagnose either rheumatoid arthritis axial spondyloarthritis , accord local practice Transition Enbrel Benepali physician 's ( Investigator 's ) discretion , within 3 month prior decision enrollment Must treat dose Enbrel least 6 month prior transition Benepali Must stable disease activity within 2 month prior enrolment base Investigator 's judgement Women childbearing potential advise use appropriate contraception avoid become pregnant Benepali therapy three week discontinuation therapy Key Have medical condition precludes administration Benepali accord Summary Product Characteristics ( SmPC ) , follow : Hypersensitivity Benepali active substance , associate excipients Sepsis , risk sepsis Active clinically significant local chronic viral , bacterial fungal infection , major episode infection require hospitalization treatment parenteral antiinfectives within 2 month prior enrollment Show clinical sign medical condition allow treatment continuation ( etanercept ) judgment Investigator Treatment another biologic agent Are currently receive previously receive therapy would preclude administration Benepali , follow : Immunizations live liveattenuated vaccine within last 6 month prior transition point throughout observation period Treatment investigational agent within last 6 month prior transition point period observation . Any unspecified reason would , opinion Investigator , make patient unsuitable enrollment . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Biosimilar , etanercept , Benepali , Enbrel</keyword>
</DOC>